Navigation Links
Harnessing Patients' Good Intentions Can Cut 33% of America's Pharmacy-Related Waste
Date:4/6/2011

ST. LOUIS, April 6, 2011 /PRNewswire/ -- The U.S. can eliminate 33 percent of its annual pharmacy-related waste simply by activating patients' good intentions to improve common behaviors linked to their prescription drugs, according to a groundbreaking research report released today. In a break with traditional views on pharmacy care, the Express Scripts 2010 Drug Trend Report shows a significant gap between patients' intentions and their actions, and recommends behavior-based solutions to bridge the difference.

(Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO)

The report includes results from a Harris Interactive study, commissioned by Express Scripts (Nasdaq: ESRX), that confirms the gap between what patients intend and what they do. The study found that 82 percent of patients who use brand-name medications actually prefer generics. Similarly, 70 percent of those using a retail pharmacy to fill medications for chronic conditions prefer to use a home delivery pharmacy, given the financial incentives for home delivery that are common to many plans.

If all patients consistently used generics, low-cost brands, and home delivery when available and appropriate, and adhered to their medication therapy, the nation could cut as much as $403 billion a year in unnecessary spending, the report states. However, a third of the total waste -- $134 billion -- can be eliminated simply by making it easy for patients to act on their existing good intentions. This is equivalent to saving $434 per year for every man, woman and child in America.

"Don't let behavior fool you," said Bob Nease, PhD, chief scientist at Express Scripts. "Patients' behavior is often misleading and doesn't represent their underlying intention. Our research and experience show that most patients, when presented with a choice, make decisions that lower costs and improve their health -- decisions that also are in the plan sponsor's best interest."

"These findings reframe conventional thinking. The disparity in healthcare is not between what plan sponsors want and what patients want, but between what patients want and what they actually do. Optimal healthcare outcomes are possible only with an advanced understanding of behavior."

James Klein, president of the American Benefits Council, said the report has significant implications for employer-sponsored healthcare.

"Activating consumer intent is a win-win for employers and employees," he said. "Engaging tools that help people make decisions will lead to more cost-effective quality outcomes, which is essential to health system reform."

Express Scripts, a recognized leader in the application of the behavioral sciences to healthcare, recently opened its Research & New Solutions Lab in St. Louis. At the Lab, researchers mine data to understand why patients make the decisions they do, how they interact with their drug therapies, and what practical solutions will improve health and lower costs while preserving patient choice.

The Drug Trend Report also quantifies changes in drug trend on a year-to-year basis, using Express Scripts claims data.

Overall, drug trend in the U.S. increased 3.6 percent, down from 6.4 percent in 2009. Trend for traditional medications fell by more than half, while specialty-drug trend continued its rapid growth with a 19.6 percent increase. Specialty trend has had double-digit growth every year since 2004, when Express Scripts began tracking it separately from traditional trend.  

Other notable trends from 2010 include 12.5 percent trend growth among diabetes drugs, which are poised to become the single largest driver of trend in the next several years. Meanwhile, ulcer disease drug spend dropped 13.7 percent as an increasing number of generics and over-the-counter options joined the class.

The full report is available at www.express-scripts.com/research/studies/drugtrendreport.

About Express Scripts

Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, is leading the way toward creating better health and value for patients through Consumerology®, the advanced application of the behavioral sciences to healthcare. This approach is helping millions of members realize greater healthcare outcomes and lowering cost by assisting in influencing their behavior. Headquartered in St. Louis, Express Scripts provides integrated PBM services including network-pharmacy claims processing, home delivery services, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services. More information can be found at http://www.express-scripts.com/pressroom/ and http://www.consumerology.com/.

Media Contact: Thom Gross
314.684.6321 or 314.922.6226
RTGross@express-scripts.com


'/>"/>
SOURCE Express Scripts, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. Many Heart Attack Patients Dont Get Best Emergency Treatment
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Center has been recognized for adherence to the highest standards of trauma, ... accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among ...
(Date:12/8/2016)... ... 2016 , ... Vida Health, the digital health platform that pairs ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect ... consumers who are managing chronic conditions or simply want to improve their ...
Breaking Medicine News(10 mins):